South Korea-based GC Cell has announced its participation in CancerX, part of the US Cancer Moonshot project. The Cancer Moonshot, an initiative by the Biden administration, aims to reduce cancer patient mortality rates by over 50% over the next 25 years. In February of this year, CancerX, a public-private collaboration led by the Moffitt Cancer Center and the Digital Medicine Society, was established to boost innovation in the fight against cancer as part of the reignited Cancer Moonshot.

CancerX boasts participation from multinational pharmaceutical companies such as Johnson & Johnson, AstraZeneca, and Takeda, along with prestigious medical institutions like MD Anderson, Mayo Clinic, and Dana-Farber Cancer Institute. Leading global IT companies, including Intel, Amazon, and Oracle, specialising in digital healthcare, AI, diagnostics, and genomics, also contribute to the ambitious goal of conquering cancer.

GC Cell is advancing clinical trials for NK cell therapy. With its affiliation, BioCentriq, a CGT-focused Contract Development and Manufacturing Organisation (CDMO) in the US, GC Cell is well-positioned to share diverse capabilities and insights in cell therapy.

The recent simultaneous initiation of clinical trials for CAR-NK cell therapy 'AB-201' in Korea and Australia marks a historic moment as the first allogeneic (off-the-shelf) cell gene therapy in South Korea. AB-201, a freeze-preservable cell gene therapy, targets solid tumors like HER2-overexpressing breast and gastric cancers. By addressing the heterogeneity of solid tumors, this introduces a promising additional treatment option for cancer patients.

Through Cancer Moonshot participation, GC Cell aims to highlight the importance and potential of cell therapy in cancer treatment. GC Cell has submitted plans for Phase 1 clinical trials of CAR-NK cell therapy 'AB-201' to the South Korean Ministry of Food and Drug Safety and Australian Human Research Ethics Committee (HREC) is awaiting the results.